The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Genuine Biotech Limited 真實生物科技有限公司 (Incorporated in the Cayman Islands with limited liability) WARNING The publication of this announcement is req ...

Core Insights - Jade Biosciences, Inc. is advancing its investigational anti-APRIL monoclonal antibody, JADE101, for the treatment of immunoglobulin A nephropathy (IgAN), presenting new data at the ASN Kidney Week 2025 [1][2] Group 1: Product Overview - JADE101 selectively inhibits APRIL, a key factor in IgAN, which can lead to end-stage kidney disease [2] - The drug is designed for subcutaneous dosing, with a favorable pharmacokinetic and pharmacodynamic profile demonstrated in non-human primates (NHPs) [2][7] - JADE101 has shown a serum half-life of approximately 27 days, allowing for infrequent dosing [7] Group 2: Clinical Development - A Phase 1 trial is currently evaluating JADE101 in healthy volunteers, with interim data expected in the first half of 2026 to inform future studies in IgAN patients [2][8] - The trial aims to establish optimal dosing based on biomarker responses that correlate with clinical activity in IgAN patients [8] Group 3: Safety and Efficacy Data - Preclinical studies indicate that JADE101 is well tolerated in NHPs, with no observed adverse effects at the highest doses tested [5] - JADE101 treatment resulted in significant reductions in serum immunoglobulins, including IgA and IgM reductions of approximately 55–68% and 62–75%, respectively, without broad immunosuppression [5][6] - The drug demonstrated no off-target binding and did not affect immune cell populations, supporting its potential as a safe treatment option [5][6] Group 4: Biomarker Insights - Analyses suggest that pharmacokinetic and biomarker responses in healthy volunteers can predict therapeutic outcomes in IgAN patients [6][11] - The depth and duration of APRIL suppression are linked to reductions in total IgA and proteinuria, which are associated with preserving kidney function [6][11] Group 5: Company Background - Jade Biosciences focuses on developing therapies for autoimmune diseases, with JADE101 as its lead candidate targeting APRIL [9] - The company also has other candidates in its pipeline, including JADE201 and JADE-003, currently in preclinical development [9]

Core Viewpoint - MoonLake Immunotherapeutics is facing a securities class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab, leading to significant stock price declines after disappointing trial results [2][4][5][7][8]. Group 1: Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [5]. Group 2: Allegations and Legal Action - The lawsuit claims that MoonLake and its executives violated federal securities laws by providing misleading information about the clinical benefits of sonelokimab [2][4][6]. - The complaint is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in MoonLake common stock [4]. Group 3: Clinical Trial Results and Impact - MoonLake reported disappointing results from the VELA Phase 3 trials on September 28, 2025, with VELA-2 failing to meet its primary endpoint, raising doubts about the drug's regulatory approval and commercial viability [8]. - Following the announcement, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [8].

Core Insights - REGENXBIO Inc. reported a GAAP EPS loss of -$1.20 for Q3 2025, which exceeded estimates by approximately $0.14 [1] - The company's revenue for the same quarter was $29.7 million, reflecting a year-over-year increase of 22.7% and surpassing expectations by about $5.29 million [1] Financial Performance - Q3 2025 GAAP EPS loss: -$1.20, beating estimates by $0.14 [1] - Revenue: $29.7 million, up 22.7% year-over-year, exceeding expectations by $5.29 million [1]

Core Insights - Amgen, Inc. is one of the largest biotechnology companies in America and globally [1] Company Performance - The stock performance of Amgen has been quite volatile over the past 52 weeks [1]

Core Insights - Amgen, Inc. is one of the largest biotechnology companies in America and globally [1] Company Performance - The stock performance of Amgen has been quite volatile over the past 52 weeks [1]

Core Insights - 10x Genomics reported third-quarter financial results that exceeded Wall Street expectations, leading to a 14.3% increase in share price [1][2] - The company projected fourth-quarter revenue between $154 million and $158 million, surpassing analysts' forecasts, indicating strong confidence in future performance [2] Financial Performance - For Q3, 10x Genomics generated revenue of $149 million, above the consensus estimate of $142.4 million [2] - The loss per share was $0.22, which was narrower than the anticipated loss of $0.28 [2] - The stock closed at $15.25, reflecting a 17.4% increase from the previous close [3] Market Reaction - The shares of 10x Genomics have shown extreme volatility, with 48 moves greater than 5% in the past year, indicating significant market impact from recent news [4] - The previous notable stock movement occurred 18 days prior, when the stock rose 6% after BofA Securities maintained a "Buy" rating while lowering the price target from $15.00 to $13.00 [5] Investment Performance - Year-to-date, 10x Genomics shares are up 7.5%, trading close to a 52-week high of $16.47 [6] - An investment of $1,000 in 10x Genomics shares five years ago would now be valued at $113.74 [6]

Core Insights - Surrozen, Inc. is focused on developing targeted therapeutics that modulate the Wnt pathway for tissue repair and regeneration, particularly in severe eye diseases [1][2] Business Highlights - The company is concentrating on its ophthalmology pipeline, utilizing its expertise in Wnt biology and antibody technologies to create new treatments for severe eye diseases [2] Leadership Changes - Andrew Maleki has been appointed as Chief Financial Officer, bringing over a decade of biotech experience and a track record of raising over $500 million in capital [4][5] - Charles Williams will continue as Chief Operating Officer, focusing on strategic initiatives and corporate development [6][7] Financial Performance - As of September 30, 2025, cash and cash equivalents were $81.3 million, down from $90.4 million as of June 30, 2025 [8] - Collaboration and license revenue was zero for the quarter, compared to $10 million for the same period in 2024, due to the recognition of a milestone in September 2024 [8] - The net loss for the quarter was $71.6 million, or $8.36 per share, compared to a net loss of $1.4 million, or $0.44 per share, for the same period in 2024 [13][23] Ophthalmology Pipeline - Surrozen is advancing its lead candidates, SZN-8141 and SZN-8143, for retinal diseases and plans to submit an Investigational New Drug (IND) application for SZN-8141 in 2026 [9] - SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism, showing potential benefits over existing treatments for Diabetic Macular Edema (DME) and wet Age-Related Macular Degeneration [14] - SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism, which may offer advantages for treating DME, wet AMD, and uveitic macular edema [15] Strategic Partnerships - Surrozen has a partnership with Boehringer Ingelheim for SZN-413, a bi-specific antibody targeting Fzd4-mediated Wnt signaling, which has shown promise in preclinical models for retinal diseases [16][18]

Core Viewpoint - Rosen Law Firm is urging investors of Jasper Therapeutics, Inc. to contact them regarding a class action lawsuit due to allegations of misleading business operations [1][2]. Summary by Sections Allegations - The lawsuit claims that Jasper Therapeutics made false and misleading statements, including: - Lack of necessary controls and procedures for third-party manufacturers to comply with cGMP regulations [3]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects of products like briquilimab [3]. - Potential for disruptive cost-reduction measures due to the aforementioned failures [3]. - Overstated business and financial prospects, as well as clinical and commercial prospects of briquilimab [3]. - Public statements made by defendants were materially false and misleading [3]. Class Action Participation - Investors may be eligible to participate in the class action against Jasper Therapeutics, with a deadline to file motions for lead plaintiff by November 18, 2025 [4]. - Investors do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Rosen Law Firm Background - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [6].

Core Insights - China's commitment to innovation is reshaping its economy, transitioning from a manufacturing hub to a center for technological advancement, particularly in sectors like pharmaceuticals, AI, and robotics [2][3][6] - Despite the surge in high-tech innovation, China's economy faces significant challenges, including declining retail sales, a shrinking population, and a struggling property market [4][5][10] Industry Developments - XtalPi Holdings exemplifies China's shift towards innovation, utilizing AI to accelerate drug discovery and forming partnerships with major Western pharmaceutical companies [1][2] - China's R&D spending is increasing at nearly 9% annually, significantly outpacing the U.S. at 1.7%, with a record 70,160 international patents filed in 2024 [3][4] - The MSCI China index has risen by 43% in 2025, outperforming the S&P 500, indicating a strong recovery in the stock market driven by technological advancements [4][26] Economic Challenges - Despite advancements, China's economy is projected to grow only 3% to 4% annually in the coming years, a stark decline from previous growth rates of 6% to 8% [5][12] - The property sector, which previously accounted for about 25% of GDP, is expected to remain significantly diminished, potentially at only 40% of its original size [11][12] - Consumption remains low, with China accounting for only 12% of global consumption despite being responsible for 27% of global investment [12][13] Government Initiatives - Beijing is prioritizing sectors like AI, pharmaceuticals, and semiconductors, with substantial government investment projected at 600 billion to 700 billion yuan ($84 billion to $98 billion) for AI alone [7][15] - Recent policy shifts indicate a recognition of the need to boost domestic consumption, with plans for cash transfers and support for families [13][14] Global Implications - China's technological advancements pose a competitive threat to U.S. companies, reminiscent of past economic shifts that impacted global manufacturing [8][9] - The ongoing trade tensions and restrictions from the U.S. are accelerating China's push for self-sufficiency in technology, particularly in semiconductors and AI [18][22] - As Chinese companies expand globally, they are increasingly focusing on domestic suppliers, which may exacerbate trade tensions [21][22] Investment Opportunities - The current market dynamics suggest potential for a new bull market in China, with foreign investors encouraged to explore sectors like IT and advanced industrials [20][28] - Chinese stocks may become a more attractive option for domestic investors, especially if the government successfully stimulates economic growth and innovation [30]